BCC-014-DFMO
Phase II
OPEN TO ACCRUAL
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
BCC-015
Phase II
OPEN TO ACCRUAL *
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
COG-AREN1921
Phase II
OPEN TO ACCRUAL *
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
PIDTC-CSIDE
Phase II
OPEN TO ACCRUAL *
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR alpha beta+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC CSIDE Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801